匯證:維持偉能(1608.HK)買入評級 新增產能將帶動增長
匯豐證券發表研究報告指出,偉能集團(1608.HK)陸續有項目投入營運,有助提升集團未來兩年產能約70%,從而帶動盈利年均復增長率接近20%,暫時新型肺炎並未對偉能業務造成重大的影響,匯證認為其估值吸引,維時“買入”評級及目標價3.2港元不變。
報告指出,偉能集團於過去數月致力在緬甸及斯里蘭卡加快步伐穩固投資、建設及營運項目。該行預料,偉能2019年度業績將有不俗的增長,並持續看好集團透過獲得緬甸項目鞏固其強勁增長。
報告又説,在新型冠狀病毒肺炎疫情下,由於集團超過65%的系統集成業務分佈在亞洲國家,包括新加坡、阿拉伯聯合酋長國、緬甸、印度及南韓,其業務僅受輕微影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.